Navigation Links
EntreMed Reports Third Quarter 2008 Financial Results
Date:11/6/2008

ROCKVILLE, Md., Nov. 6 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today reported results for the three- and nine-month periods ending September 30, 2008.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

Revenues for the third quarter 2008 were approximately $3,501,000 versus $3,520,000 for the comparable period a year ago. The Company reported a net loss for the third quarter of approximately ($3.4 million) or ($0.04) per share. This compares with a net loss of approximately ($3.0 million), or ($0.04) per share for the same period last year.

Revenues for the nine months ended September 30, 2008 were approximately $3,501,000 versus $3,520,000 for 2007. Reported net loss for the first nine months of 2008 was ($21.3 million), or ($0.26) per share as compared to ($18.6 million) or ($0.23) per share for 2007. As of September 30, 2008, EntreMed had cash and short-term investments of approximately $28 million.

Dane R. Saglio, EntreMed Chief Financial Officer, commented, "We have estimated that the royalty revenue from sales of Thalomid(R) for the 3rd quarter will be $3.5 million and we expect royalty revenue for the year to increase over 2007 with Celgene's acquisition of Pharmion Corporation. Research and development expenses for the third quarter declined versus the prior quarters in 2008 due in part to the decision made earlier in the year to discontinue the use of Panzem in oncology, but also impacted by a decreasing number of patients being treated with MKC-1 related to Phase 2 trials ini
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. EntreMeds ENMD-2076 Demonstrates Tumor Regression in Human Colon Cancer Model
2. EntreMed to Present at BioPartnering Europe Conference
3. EntreMed Announces Stock Listing Transfer to Nasdaq Capital Market
4. EntreMed Reports Second Quarter 2008 Financial Results
5. EntreMed Appoints Thomas H. Bliss as Senior Vice President of Corporate and Business Development
6. Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMeds Selective Kinase Inhibitor
7. EntreMed Will Not Seek Shareholder Approval for Reverse Stock Split at Annual Meeting
8. EntreMeds Kinase Inhibitor, ENMD-2076, Presented During AACR Special Session
9. EntreMed Receives Nasdaq Deficiency Notice
10. EntreMed to Present at BioCentury Future Leaders in the Biotech Industry Conference
11. EntreMed Announces 2008 Corporate and Clinical Program Priorities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 EPFL ... announce the appointment of John P. Donoghue . ...   in  Geneva . The new ... Biotech in Geneva , has named ... neuroscientists. John P. Donoghue , founder of Brown ...
(Date:7/10/2014)... 10, 2014 Product and process ... low abundance and are often “lost in the ... , Join presenters Dr. Rowel Tobias, Senior Scientist, ... Anders, Head of Quality at Nanotherapeutics, Inc., to ... can speed detection and quantitation while achieving the ...
(Date:7/10/2014)... Poway, CA (PRWEB) July 10, 2014 Robert ... Regenerative Veterinary Medicine company, is proud to announce the relaunch ... Pets, launching with a new series called “ What are ... to give an honest and straightforward foundation in the basics ... an educated decision on the right type of treatment when ...
(Date:7/10/2014)... , July 10, 2014 ... Dmitry Medvedev , presented Russia,s ... BIOCAD . The Company is developing a unique ... MabNext project BIOCAD develops a number of innovative drugs ... autoimmune diseases. The ceremony took place at the International ...
Breaking Biology Technology:John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 2John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 3Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2
... Wis. - After months of debate and restructuring Gov. ... - at the expense of the Biomedical Technology Alliance ... exercising a partial veto on a proposed grant of $2.5 ... investors located in southeastern Wisconsin. The partial veto will cut ...
... BIO 2005 meeting in Philadelphia last month, the globalization of ... flight. The company that perhaps best chronicles and tracks this ... biotechnology. , ,This report is usually released and previewed at ... appropriate title Beyond Borders: Global Biotechnology Report 2005, is a ...
... two-year state budget signed into law Monday by Gov. ... Wisconsin technology firms by changing how corporate income from ... Technology Council. , ,With bipartisan support from the ... factor" sales apportionment for corporate income to technology and ...
Cached Biology Technology:Doyle partially vetoes SE Wisconsin technology grant 2Doyle partially vetoes SE Wisconsin technology grant 3Globalization of biotech industry is a decidedly worldwide phenomenon 2Globalization of biotech industry is a decidedly worldwide phenomenon 3`Single-sales factor' extends tax treatment to tech, service firms 2`Single-sales factor' extends tax treatment to tech, service firms 3
(Date:7/11/2014)... Researchers from Ume University, Sweden, have explored two ... the reaction sequence leading to the formation of ... been published in the scientific journal Nature ... improving present day synthetic catalysts for water oxidation, ... devices for the direct storage of solar energy ...
(Date:7/11/2014)... the normal circumstances, astrocytes participate in normal ... and exhibit therapeutic and repairing effects on ... have found that nerve cells differentiated from ... reduced viability, which produces influences on subsequent ... General Hospital, Hebei United University, China demonstrated ...
(Date:7/10/2014)... and other major cities in New Mexico, nearly every ... wastewater rather than precious potable water supplies. Across the ... all golf courses receive treated effluent. Reusing the effluent ... golf courses and homeowners alike fertilize their lawns during ... nitrate. A New Mexico State University turfgrass expert has ...
Breaking Biology News(10 mins):Molecular snapshots of oxygen formation in photosynthesis 2'Tailored' water -- the latest in lawn care 2
... to find the necessities of life. It,s a complex task, ... environment to navigate the safest and fastest routes to food ... certain important events, such as finding a meal, will occur. ... fundamental behaviors, navigation and the anticipation of a reward, had ...
... /PRNewswire-iReach/ -- IdentiSys Inc., North America,s ... emergency response, and access control security systems, today announced ... in Customer and Patient Experience Management systems. IdentiSys will ... to the marketplace and will be the only North ...
... re-growing tropical forests has concluded that plant biodiversity takes ... such as clearance for farming. The findings, ... Royal Society B , have important implications for conservation ... and Central America. The new study is the first ...
Cached Biology News:Anticipation and navigation: Do your legs know what your tongue is doing? 2Anticipation and navigation: Do your legs know what your tongue is doing? 3Anticipation and navigation: Do your legs know what your tongue is doing? 4IdentiSys brings Qmatic Q-Guide Queuing Systems to the North American market 2IdentiSys brings Qmatic Q-Guide Queuing Systems to the North American market 3Carbon storage recovers faster than plant biodiversity in re-growing tropical forests 2
IMAGEQUANT 100 IQTL, 1 EA. Category: ImageQuant CCD Imagers....
Request Info...
RayBio Human Cytokine Antibody Array 1.1 (4 array membranes) with Accessory, detects 20 cytokines (for lysate) Class: Antibody Array Products Product Group: Antibody Array...
...
Biology Products: